Drug-Induced Interstitial Lung Disease in a patient treated with a combination of palbociclib and fulvestrant
https://doi.org/10.4081/cdr.11.11679
Accepted: 26 October 2023
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
A 59-year-old patient without a history of pulmonary disease presented with episodes of hemoptysis and acute respiratory failure after being treated for metastatic breast cancer with fulvestrant and palbociclib. The high-resolution chest CT revealed diffuse ground glass opacities and diffuse smooth thickening of the interlobular septa and peribronchovascular interstitium, consistent with drug-induced interstitial lung disease (DIILD). A few days of high-dose steroid treatment increased the patient's PaO2/FiO2 from 75 to 200. Following hospital discharge, the oncologist resumed fulvestrant therapy, with no further adverse events occurring during subsequent follow-up.
(1) Spagnolo P, Bonniaud P, Rossi G, et al. Drug-induced interstitial lung disease. European Respiratory Journal 2022;60:2102776. DOI: https://doi.org/10.1183/13993003.02776-2021
(2) Skeoch S, Weatherley N, Swift A, et al. Drug-Induced Interstitial Lung Disease: a Systematic Review J Clin Med 2018;7:356. DOI: https://doi.org/10.3390/jcm7100356
(3) Levy O, Ptashkin E, Shechtman Y, et al. Fatal Palbocyclib-Related Interstitial Pneumonitis. Archives of Clinical and Medical Case Reports 2019;3:162-6.
(4) Zhang Y, Ma Z, Sun X, et al. Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials. Breast 2022;62:162-9. DOI: https://doi.org/10.1016/j.breast.2022.02.011
(5) Raschi E, Fusaroli M, Ardizzoni A, et al. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat 2021;186:219-27. DOI: https://doi.org/10.1007/s10549-020-06001-w
(6) Di Cosimo S, Pérez-García JM, Bellet M, et al. Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial. Oncologist 2023;28:23-32. DOI: https://doi.org/10.1093/oncolo/oyac205
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
